Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT00090545
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: Placebo
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 501
- Registration Number
- NCT00079612
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: Placebo
- First Posted Date
- 2003-11-21
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 903
- Registration Number
- NCT00073307
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 342
- Registration Number
- NCT00064350
- Locations
- 🇺🇸
Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States
🇺🇸Memorial Hospital, Carthage, Illinois, United States
🇺🇸St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States
A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2002-09-04
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 137
- Registration Number
- NCT00044512
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.